Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable...
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
About this item
Full title
Author / Creator
Melisi, Davide , Garcia-Carbonero, Rocio , Macarulla, Teresa , Pezet, Denis , Deplanque, Gael , Fuchs, Martin , Trojan, Jorg , Oettle, Helmut , Kozloff, Mark , Cleverly, Ann , Smith, Claire , Estrem, Shawn T. , Gueorguieva, Ivelina , Lahn, Michael M. F. , Blunt, Al , Benhadji, Karim A. and Tabernero, Josep
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was determined.
Methods
This was a two-part, multin...
Alternative Titles
Full title
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6251034
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6251034
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-018-0246-z
